Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 5Head & Neck 3Thoracic 2Sarcoma 2Endocrine 2Plasma cell 1Other solid neoplasm 1Other hematologic neoplasm 1NET 1Gynecologic 1Dermatologic 1CNS 1Breast 1

Conditions

Ovarian Neoplasms 15Uterine Cervical Neoplasms 7Endometrial Neoplasms 7Fallopian Tube Neoplasms 6Parkinson Disease 4, Autosomal Dominant Lewy Body 5Carcinoma, Renal Cell 4Carcinoma, Ovarian Epithelial 4Pancreatic Neoplasms 3Melanoma 3Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Urinary Bladder Neoplasms 2Thyroid Neoplasms 2Small Cell Lung Carcinoma 2Sarcoma 2Salivary Gland Neoplasms 2Neuroendocrine Tumors 2Lung Neoplasms 2Head and Neck Neoplasms 2Esophageal Neoplasms 2Cholangiocarcinoma 2Carcinoma, Hepatocellular 2Brain Neoplasms 2Vulvar Neoplasms 1Uterine Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Cancer, Papillary 1Testicular Neoplasms 1Teratoma 1

Interventions

pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × Biliary Tract Neoplasms × Gynecologic × Clear all
NCT02628067 2025-09-22

KEYNOTE 158

Merck Sharp & Dohme LLC

Phase 2 Active not recruiting
1,609 enrolled 4 FDA
EndocrineGastrointestinalGynecologicHead & NeckNETOther solid neoplasmThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Anus Neoplasms, Bile Duct Neoplasms, Biliary Tract Neoplasms, Carcinoid Tumor, Uterine Cervical Neoplasms, Mesothelioma, Parotid Neoplasms, Salivary Gland Neoplasms, Thyroid Neoplasms, Vulvar Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Neuroendocrine Tumors, Microsatellite Instability, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡